14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
JNJ vs BOLD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Johnson & Johnson (JNJ) is the stronger overall head-to-head candidate over Boundless Bio, Inc. (BOLD) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). JNJ carries a Unified Composite Score of 57.8/100 (HOLD) at $270.47 (23.3x Forward P/E, 26.6% operating margin), whereas BOLD carries 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: JNJ trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 48.1); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on JNJ vs BOLD. Trailing 12-month operating profitability (JNJ 26.6% vs BOLD 0.0%) and valuation multiples (JNJ 23.3x vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ JNJ vs BOLD Key Questions & Quantitative Answers
As of Nov 20, 2026, Johnson & Johnson (JNJ) is the stronger overall head-to-head candidate over Boundless Bio, Inc. (BOLD) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). JNJ carries a Unified Composite Score of 57.8/100 (HOLD) at $270.47 (23.3x Forward P/E, 26.6% operating margin), whereas BOLD carries 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: JNJ trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 48.1); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
JNJ leads the Growth & Scale pillar: JNJ posts +5.9% YoY revenue growth and -95.9% YoY earnings growth on $99.3B TTM revenue (67.8% gross margin, 26.6% operating margin), compared with BOLD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, JNJ generates $99.3B in USD-normalized revenue versus N/A for BOLD. In operating R&D and SG&A reinvestment, JNJ deploys 41.2% of Rev ($40.9B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BOLD.
JNJ screens cheaper on headline valuation multiples. JNJ trades at 23.3x Forward P/E, 40.5x Trailing P/E, 3.07x PEG, and 6.8x EV/Revenue (19.7% FCF margin), whereas BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against JNJ (20.0% ROE) versus BOLD (-64.6% ROE) capital efficiency.
In options market volatility and institutional positioning, JNJ carries 34.7% implied volatility (45th %ile, Balanced (25th–60th %ile)), a 0.76x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.04β · 25% Vol realized risk). By comparison, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.